In Vitro Desensitization of Human Skin Mast Cells

UNCG Author/Contributor (non-UNCG co-authors, if there are any, appear on document)
Christopher Kepley, Associate Professor (Creator)
The University of North Carolina at Greensboro (UNCG )
Web Site:

Abstract: Desensitization is a clinical procedure whereby incremental doses of a drug are administered over several hours to a sensitive patient until a therapeutic dose and clinical tolerance are achieved. Clinical tolerance may occur in part by attenuating the mast cell response. In the present study, primary human skin mast cells were used to establish and characterize an in vitro model of desensitization. Mast cells in culture were armed with allergen-specific (4-hydroxy-3-nitrophenylacety and Der p2) and non-specific IgE antibodies, and then desensitized by incremental exposures to 4-hydroxy-3-nitrophenylacety-BSA. This desensitization procedure abrogated the subsequent degranulation response to the desensitizing allergen, to an unrelated allergen, and to IgG anti-FceRI, but not to C5a, substance P, compound 48/80, and calcium ionophore. Desensitized cells regained their FceRI-dependent degranulation capability by 24–48 h after free allergen had been removed. Therefore, sensitized human skin mast cells are reversibly desensitized in vitro by exposure to incremental doses of that allergen, which also cross-desensitizes them to an unrelated allergen. Abbreviations NP: 4-hydroxy-3-nitrophenylacetyl %DegDD: %degranulation during desensitization %Des: %desensitization

Additional Information

Journal of Clinical Immunology, 32(1):150-60
Language: English
Date: 2012
Mast cell, desensitization, IgE, tolerance, allergy, Syk, Lyn, Fyn, CD63

Email this document to